Results 131 to 140 of about 170,479 (217)

Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma. [PDF]

Hematol Oncol
Itonaga H, Fukushima T, Muranushi H, Nakano N, Inoue Y, Tokunaga M, Fukuda T, Eto T, Kawakita T, Kato T, Ishikawa J, Yoshimitsu M, Uchida N, Mori Y, Saburi M, Suehiro Y, Ogata M, Kanda Y, Ishitsuka K, Atsuta Y, Fuji S.   +20 more
europepmc   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, EarlyView.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source

From Genomic and Epigenomic Maps to Medicines in Adult T-Cell Leukemia/Lymphoma. [PDF]

Cancer Sci
Suzuki K, Yamagishi M.
europepmc   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, EarlyView.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Concurrent sigmoid colon adenocarcinoma presenting with cutaneous adult T-cell leukemia/lymphoma: a rare case report. [PDF]

Infect Agent Cancer
Maharati A, Zangooie A, Eydgahi MS, Haghshenas H, Eghbali Z, Meibodi NT, Salehi Z, Allahyari A.   +7 more
europepmc   +1 more source

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative strategy for acute myeloid leukemia (AML), but the impact of HLA disparity in the era of posttransplant cyclophosphamide (PTCy) and reduced‐toxicity conditioning remains unclear. We performed an EBMT registry study including 275 adult AML patients in first
Daniele Avenoso, Mirko Farina, Michele Malagola, Yves Chalandon, Giorgia Saporiti, Annalisa Imovilli, Enrico Derenzini, Peter Remenyi, Massimo Martino, Maija Itala‐Remes, Renato Fanin, Didier Blaise, Desiree Kunadt, Arancha Bermudez Rodriguez, Franca Fagioli, Thomas Schroeder, Irene Cavattoni, Maud Ngoya, Mohamed Houhou, Mohamad Mohty, Eolia Brissot, Fabio Ciceri   +21 more
wiley   +1 more source

Coexistence of EZH2, NOTCH1, IL7R, and PHF6 Mutations in Adult T-cell Acute Lymphoblastic Leukemia

Turkish Journal of Hematology, 2017
Xilian Zhou, Yan Gu, Qi Han, Mario Soliman, Chunhua Song, Zheng Ge   +5 more
doaj   +1 more source

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

American Journal of Hematology, EarlyView.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos   +49 more
wiley   +1 more source

Differential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in Neuroblastoma

Angewandte Chemie, EarlyView.
BZ2 is a second‐generation Bromodomain PHD finger Transcription Factor (BPTF) inhibitor with improved selectivity over Class I and Class IV BRD off‐targets identified in our previously reported inhibitor, BZ1. Structural analyses reveal that water network engagement is key to this selectivity.
Kesavan Babu, Chun‐Ju Tsou, Sourav Das, Liying Fan, Anasuya Pal, Molly Sneddon, Timothy R. Stachowski, Priyanka Samanta, Stanley Nithianantham, Caroline Buchholz, Shi Zhang, Xiang Fu, Rahul S. Kathayat, Wenwei Lin, Yongtao Li, Lei Yang, Taosheng Chen, Marcus Fischer, Anang A. Shelat, William C. K. Pomerantz   +19 more
wiley   +2 more sources

Prognostic impact of morphological lymphocyte counts on aggressive adult T-cell leukemia/lymphoma: Japan ATL nationwide registry analysis. [PDF]

Blood Cancer J
Jimbo K, Ito A, Horibe E, Yagishita N, Makiyama J, Itonaga H, Miyazono T, Nosaka K, Yoshimitsu M, Choi I, Kawano N, Koh KR, Otsuka E, Nakashima H, Yamano Y, Nannya Y, Fukuda T, Japan Aggressive ATL Consortium.   +17 more
europepmc   +1 more source